New targets featured at AACR signal growing opportunity in established mechanisms
Protein degraders, ion channel regulators and novel checkpoints are among new targets presented at AACR21
The bulk of the new targets presented at AACR21 involve pathways and mechanisms active in tumor cells rather than immune cells, reflecting the biotech industry’s growing interest in targeted oncology and precision medicine.
BioCentury’s analysis of the abstracts presented at the American Association for Cancer Research (AACR) annual meeting identifies 47 new targets that aren’t addressed by any cancer programs in clinical or preclinical development, according to BioCentury’s BCIQ database. ...